Abstract
Abstract Purpose To investigate the effect of intravitreal ketorolac tromethamine in chronic post‐operative cystoid macular edema. Methods Six patients diagnosed with chronic post‐operative CME non responsive in conventional therapies, were enrolled. 2 patients received 2 intravitreal injections of 300 μg (0.05ml) of ketorolac tromethamine (Toradol) with a 3‐week interval, three patients received 4 consecutive injections of 500 μg (0.05ml) weekly and 3 patients received 4 consecutive injections of 500 μg (0.05ml) daily. Patients were followed by means of biomicroscopy, fluorescein angiography and optical coherent tomography. Follow‐up lasted up to six months. Results No adverse effect was noticed in any of the patients. A trend for visual acuity improvement and macular edema regression was noticed after initiation of the therapy. A rebound of the edema happened usually a week after the last injection. In the long follow‐up regression of the macular edema was noticed in three out of six patients. Conclusion This pilot study indicates a possible role of intravitreal injection of ketorolac tromethamine in patients with chronic postoperative cystoid macular edema. Further research is warranted in order to obtain conclusive results concerning doses and timing of injections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
